Peel Hunt restated their buy rating on shares of Vectura Group PLC (LON:VEC) in a research note released on Wednesday morning. They currently have a GBX 200 ($2.50) price objective on the stock.

Several other equities research analysts have also recently weighed in on VEC. N+1 Singer reissued a buy rating and issued a GBX 208 ($2.60) price objective on shares of Vectura Group PLC in a research report on Tuesday. Stifel Nicolaus reaffirmed a buy rating and issued a GBX 242 ($3.02) target price on shares of Vectura Group PLC in a research report on Friday, July 29th. Numis Securities Ltd reaffirmed a buy rating and issued a GBX 246 ($3.07) target price on shares of Vectura Group PLC in a research report on Thursday, July 28th. FinnCap reaffirmed a buy rating and issued a GBX 225 ($2.81) target price on shares of Vectura Group PLC in a research report on Tuesday, August 30th. Finally, JPMorgan Chase & Co. reaffirmed an overweight rating and issued a GBX 230 ($2.87) target price on shares of Vectura Group PLC in a research report on Thursday, July 28th. Eight analysts have rated the stock with a buy rating, Vectura Group PLC has a consensus rating of Buy and a consensus target price of GBX 222.13 ($2.78).

Shares of Vectura Group PLC (LON:VEC) opened at 149.9277 on Wednesday. The stock’s 50 day moving average is GBX 138.31 and its 200-day moving average is GBX 147.81. The stock’s market capitalization is GBX 615.63 million. Vectura Group PLC has a one year low of GBX 122.90 and a one year high of GBX 200.10.

In other news, insider Andrew Derodra purchased 30,000 shares of the firm’s stock in a transaction that occurred on Friday, September 30th. The shares were acquired at an average price of GBX 138 ($1.72) per share, for a total transaction of £41,400 ($51,724.14). Also, insider Bruno Angelici purchased 80,000 shares of the firm’s stock in a transaction that occurred on Monday, September 26th. The stock was purchased at an average price of GBX 143 ($1.79) per share, for a total transaction of £114,400 ($142,928.54).

WARNING: This news story was originally published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2016/11/24/vectura-group-plcs-vec-buy-rating-reaffirmed-at-peel-hunt.html.

About Vectura Group PLC

Vectura Group plc is a product development company. The Company focuses on the development of pharmaceutical therapies for the treatment of airways-related diseases (airways diseases). The Company has eight products marketed by its partners and a portfolio of drugs in clinical development, a number of which have been licensed to pharmaceutical companies.

Receive News & Stock Ratings for Vectura Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group PLC and related stocks with our FREE daily email newsletter.